Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Current price: ~$25.77 Shares outstanding: ~5.70 billion Market capitalization: ~$149 billion Dividend: $1.72/yr (~6.7% yield) Forward P/E (2026E adj.): ~8.5x The two of us have spent seventy years looking for businesses we can understand, run by people we trust, protected by moats we can see, at prices that leave room for our own mistakes. Pfizer fails not on price — the stock is genuinely cheap — but on the two things that matter most. Let us walk you through the reasoning, because the cheapness is real and it is tempting, and we want to explain exactly why we would still walk past it. Pfizer is one of the largest research-based pharmaceutical companies on earth. It discovers, develops, manufactures, and sells prescription medicines and vaccines across oncology, cardiovascular/metabolic disease, immunology, vaccines, and anti-infectives.
Recent filings analysed: 10-Q (2026-08-04), 8-K (2026-08-04), 8-K (2026-06-18), 8-K (2026-06-18).
Stock screener · Superinvestor 13F holdings · Analyst sentiment · Market valuation